Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

Jia Ruan • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Antibodies Lenalidomide Rituximab

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance of a phase II study of the biologic doublet, lenalidomide plus rituximab, as initial treatment for mantle cell lymphoma.

More from Jia Ruan

5:12
Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL
Jia Ruan • 10 Dec 2022
6:56
Emerging therapies in MCL: the promise of immunotherapies
Jia Ruan • 4 Oct 2022
3:53
Treatment approaches for older patients with MCL
Jia Ruan • 4 Oct 2022
5:41
Azacitidine and CHOP in PTCL
Jia Ruan • 26 Nov 2021

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals